Andrx — Merger or Acquisition (March 2006)
14 slides from Andrx's merger presentation, Mar 14, 2006

Slide 1: Andrx Acquisition Conference Call & Webcast
Conference Call & Webcast Corona, CA March 13, 2006 Andrx Acquisition

Slide 2: Agenda
Agenda Allen Chao, Ph.D., Chairman and CEO Transaction overview and rationale Charles Slacik, EVP and Chief Financial Officer Financing Q&A

Slide 3: Note Regarding Projections and Forward-Looking Statements
Note Regarding Projections and Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Securities Litigation Reform Act. All statements included in this presentation that address activities, events or developments that Watson and Andrx expect, bel

Slide 4: Additional Information about the Transaction and Where to Find It
Additional Information about the Transaction and Where to Find It This conference call may be deemed to be solicitation material in respect of the proposed merger of Watson and Andrx. In connection with the proposed merger, Andrx will file a proxy statement with the U.S. Securities and Exchange Comm

Slide 5: Allen Chao, Ph.D. Chairman and CEO
Allen Chao, Ph.D. Chairman and CEO

Slide 6: Transaction Overview
Transaction Overview $1.9B all cash transaction Watson to acquire Andrx's common stock at $25.00 per share Expected to be accretive beginning in 2007 Closing expected in 3Q 2006 Closing subject to regulatory approvals, Andrx shareholder vote and other customary closing conditions

Slide 7: Strategic Rationale
Strategic Rationale Will strengthen Watson's capabilities in sustained- release technologies Expected increased breadth of Watson's product offerings To increase the depth of Watson's pipeline >60 ANDAs on a combined basis Complements Watson's pipeline Anda to provide financial stability and solid c

Slide 8: Andrx Attributes
Andrx Attributes Anda Cartia XT (diltiazem HCl) Diltia XT (diltiazem HCl) Taztia XT (diltiazem HCl) Metformin ER Pipeline: 30 ANDAs gToprol XL gCardizem LA gPrilosec gConcerta gBiaxin XL filmtab Generics Andrx Therapeutics 15 Drug Delivery Technologies ACTOSplus met formin XR Altoprev Fortamet Solid

Slide 9: Synergies
Synergies Corporate SG&A Overlapping projects in development

Slide 10: Charles Slacik EVP & Chief Financial Officer
Charles Slacik EVP & Chief Financial Officer

Slide 11: Financing
Financing $1.9 billion cash acquisition Financed from Watson cash reserves and committed bank financing Merger approved by boards of directors of both Watson and Andrx

Slide 12: Financial Conclusions
Financial Conclusions Expected to be accretive to earnings beginning in 2007 Anticipate no change in BBB rating expected Financial flexibility for future product acquisitions

Slide 13: Allen Chao, Ph.D. Chairman and CEO
Allen Chao, Ph.D. Chairman and CEO

Slide 14: A Stronger Watson; Well Positioned for Growth
A Stronger Watson; Well Positioned for Growth Pipeline Will strengthen pipeline of specialty products Will have over 60 ANDAs combined Technologies Will strengthen technology base with sustained release capabilities Sales and Marketing Will broaden product offering for our customers API/ Cost of Goo
Source: SEC EDGAR · DEFA14A filed Mar 14, 2006
